《2016年在研慢性阻塞性肺病药物》.pdfVIP

2 0 1 2 Medicines in Development R e p o COPD R t presented by america ’s biopharmaceutical research companies More Than 50 Medicines in Pipeline for Third Leading Cause of Death in the United States COPD Prevalence in the COPD affects United States more than 13 million in millions American adults; 13.1 more than 120,000 die from the disease each year 10.5 9.8 Today, more than 13 million American adults are America’s biopharmaceutical researchers are suffering from chronic obstructive pulmonary dis- exploring various new ways to attack this devas- ease COPD , leading to limitations in their ability tating disease. Examples of new approaches to to work, exercise and perform normal social activ- treating COPD include: ity. COPD, a chronic lower respiratory disease ? An adult stem cell therapy that targets a that includes chronic bronchitis and emphysema, 7.1 is characterized by obstruction of airflow to the protein in the blood that is often elevated in COPD. lungs that interferes with normal breathing. ? A monoclonal antibody that acts on America’s biopharmaceutical research compa- IL-1 receptors involved in inflammatory nies have 54 medicines for treating COPD in the conditions. later stages of the pipeline, meaning they are either in clinical trials or awaiting FDA review. ? A medicine that targets the underlying inflammation in COPD. Each year, more than 120,000 Americans die from the disease. In addition to robbing The quest for new medicines is intense and millions of patients of their ability to breathe financially risky. Each new medicine costs, normally, COPD costs the nation approximately on average, more than $1 billion and takes $49.9 billion, including direct healthcare costs 10 to 15 years to develop. But new scientific and other indirect costs, according to the advances are increasing our knowledge, and National Institutes of Health. researchers are using every cutting-edge tool While smoking is the main risk factor for COPD, at the